DSM BioSolutions to make Novacta's lantibiotic candidate for tests
This article was originally published in Scrip
Executive Summary
DSM BioSolutions has entered into an agreement with Novacta Biosystems of the UK, under which it will manufacture Novacta's lantibiotic candidate for pre-clinical and Phase I clinical trials, as a treatment for Clostridium difficile infection. No financial terms have been disclosed.